A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Placebo
- Registration Number
- NCT04840914
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
- Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential
- Have a body mass index (BMI) of </= 45.0 kilograms per square meter (kg/m²)
- Have chronic stable heart failure (New York Heart Association (NYHA) classification II and III) on guideline directed heart failure therapy for at least 6 months prior to enrolment
- Have not changed optimal guideline directed therapy in the last 1 month prior to screening, If treated with oral diuretics, dose must be stable for at least 2 weeks prior to screening
- Have Left Ventricular Ejection Fraction (LVEF) < 40%
- Have a record of N-terminal pro b-type natriuretic peptide (NT-ProBNP) ≥ 200 picograms per millilitre (pg/mL) or a BNP value of >/= 60 pg/mL within the past 12 months prior to screening
- Have myocardial infarction, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke in the last 90 days prior to screening
- Have acute decompensated heart failure requiring IV diuretics within 12 weeks prior to screening
- Have cardiac amyloidosis, accumulation diseases (e.g., haemochromatosis, Fabry disease), muscular dystrophies, hypertrophic cardiomyopathy, pericardial constriction, or complex congenital heart disease.
- Have any moderate-to-severe stenosis of the mitral and/or aortic valve or moderate-to severe or greater mitral and/or aortic regurgitation.
- Have a history or presence of hepatic, pancreatic, or biliary tract disorders
- Have a history of malignancy or active malignancy at screening.
- Have not had age-appropriate cancer screening as recommended by the American Cancer Society and per medical judgment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Placebo Placebo Placebo administered subcutaneously (SC). LY3461767 LY3461767 LY3461767 administered subcutaneously (SC).
- Primary Outcome Measures
Name Time Method Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Baseline through Day 90 A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
- Secondary Outcome Measures
Name Time Method Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3461767 Predose up to 48 hours post end of infusion PK: AUC of LY3461767
PK: Maximum Concentration (Cmax) of LY3461767 Predose up to 48 hours post end of infusion PK: Cmax of LY3461767
Trial Locations
- Locations (7)
Washington University
🇺🇸Saint Louis, Missouri, United States
Kanagawa Prefectural Hospital Organization Kanagawa Cardiovascular and Respiratory Center
🇯🇵Kanazawa Ward,Yokohama, Kanagawa, Japan
National Cerebral and Cardiovascular Center
🇯🇵Suita-shi, Osaka, Japan
University of North Carolina, Division of Cardiology
🇺🇸Chapel Hill, North Carolina, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
The University of Tokyo Hospital
🇯🇵Bunkyo-ku, Tokyo, Japan
Tsuchiura Kyodo Hospital
🇯🇵Tsuchiura, Ibaraki, Japan